Hypercalcemia of Malignancy

Definition

Hypercalcemia of malignancy (HCM) is clinically important cancer-associated elevation of serum calcium. Across the available studies, hypercalcemia has been operationalized using total calcium, albumin-corrected calcium, persistence over time, or severity thresholds rather than one universally consistent definition. In a contemporary head and neck squamous-cell carcinoma (HNSCC) cohort, hypercalcemia at diagnosis was defined as an albumin-corrected serum calcium >2.6 mmol/L (10.4 mg/dL). ^[8]B3b A primary-care cancer-risk study used calcium ≥2.6 mmol/L as its principal threshold. ^[4]B3b A pediatric solid-tumor study required sustained serum calcium ≥11.5 mg/dL for >1 week, thereby identifying prolonged rather than transient hypercalcemia. ^[16]B3b In a hospitalized-patient mortality study, albumin-corrected calcium was categorized as mild hypercalcemia at 10.5–11.5 mg/dL and marked hypercalcemia at >11.5 mg/dL. ^[155]

HCM should therefore be interpreted in clinical context and distinguished from other causes of hypercalcemia, including primary hyperparathyroidism and treatment-related rebound. In a US military-veteran cohort of 212 patients with hypercalcemia, 59 patients (28%) had malignant disease, demonstrating that malignancy is a major but not exclusive cause of elevated calcium. ^[154]C Primary hyperparathyroidism was specifically represented among the alternative diagnoses in that cohort. ^[154]C A surgical study of 762 patients with primary hyperparathyroidism evaluated how calcium severity and other clinical variables affect intraoperative parathyroid-hormone monitoring, reinforcing the importance of considering primary parathyroid disease when attributing hypercalcemia to cancer. ^[152]

Mechanistically, malignancy-associated hypercalcemia may reflect humoral effects, skeletal destruction, or both. In newly diagnosed multiple myeloma, hypercalcemia was specifically evaluated as arising from “humoral effects and bone damage,” and its presence was associated with adverse clinical and laboratory features. ^[7]B3b Bone metastasis is also clinically relevant because hypercalcemia is classified as a skeletal-related event in patients with metastatic breast cancer. ^[10]B3b Conversely, cessation of denosumab can produce rebound hypercalcemia independently of new tumor activity: among 21 patients with bone-metastatic breast cancer who stopped denosumab, 6 (28.6%) developed hypercalcemia. ^[13]B3b

Overall epidemiology

HCM is reported most often in patients with advanced malignancy. A contemporary HNSCC study describes hypercalcemia as the most common metabolic disorder in cancer and estimates that it affects approximately 10%–20% of patients with advanced malignancies; the study assessed locally advanced or metastatic HNSCC at treatment initiation. ^[8]B3b In a large US electronic-health-record analysis involving approximately 569,000 oncology patients treated at 565 outpatient sites, HCM prevalence was estimated by cancer type and CTCAE grade using serum calcium and albumin measurements. ^[1]B3b That analysis reported the highest rates in multiple myeloma and the lowest rates in colorectal and prostate cancer, although prevalence varies according to tumor mix, disease stage, laboratory definition, and ascertainment method. ^[1]B3b

Hypercalcemia in primary care is also a marker of occult or subsequently diagnosed cancer. Among 54,267 patients aged 40 years or older with calcium results, 1,674 (3%) had calcium ≥2.6 mmol/L. ^[4]B3b Hypercalcemia was associated with cancer diagnosed during the subsequent year, with stronger association in men than women: odds ratio 2.92 in men and 1.86 in women. ^[4]B3b The corresponding positive predictive value for cancer was 11.5% in men and 4.1% in women, despite hypercalcemia being more common among women in that population. ^[4]B3b

Tumor-specific patterns

Multiple myeloma is one of the malignancies most strongly associated with HCM. In a retrospective cohort of 357 patients with newly diagnosed symptomatic multiple myeloma, 16.8% presented with hypercalcemia at diagnosis. ^[7]B3b Hypercalcemia was associated with higher β2-microglobulin, creatinine, phosphorus, uric acid, and procollagen I N-terminal propeptide levels, and the study concluded that both humoral effects and bone damage contribute to adverse outcomes. ^[7]B3b An earlier cohort of 338 newly diagnosed stage II–III myeloma patients reported bone lesions in 72.2%, providing clinical context for the skeletal component of calcium dysregulation in myeloma. ^[112]B2b

HCM is also relatively frequent in diffuse large B-cell lymphoma (DLBCL). In a cohort of 305 patients, hypercalcemia at diagnosis, defined as calcium >10.5 mg/dL, occurred in 23% of de novo DLBCL and 26% of transformed indolent lymphoma. ^[9]B3b In de novo DLBCL, hypercalcemia was strongly associated with high-risk disease features and a short interval from diagnosis to treatment. ^[9]B3b

Squamous-cell malignancies represent another important clinical phenotype. A single-center series of 220 patients with biopsy-proven squamous-cell carcinoma and a first episode of cancer-associated hypercalcemia reported a median age of 55 years and median survival of only 64 days from the hypercalcemic episode. ^[14]B3b Corrected calcium >3.0 mmol/L, hypoalbuminemia, and brain metastases were independent adverse prognostic factors. ^[14]B3b A separate study of 260 patients treated with intravenous diphosphonates likewise reported median survival of 64 days; corrected calcium >2.83 mmol/L, albumin <35.5, squamous-cell carcinoma, bone metastases, and liver involvement were associated with poorer survival. ^[111]C4

HCM is uncommon in children with solid tumors. A 25-year retrospective pediatric study identified 39 patients younger than 21 years with a solid tumor and prolonged hypercalcemia using the threshold of ≥11.5 mg/dL for >1 week; the investigators emphasized that pediatric hypercalcemia is rare and may cause severe renal insufficiency and osteoporosis. ^[16]B3b Rare tumor entities may nonetheless present in young patients: small-cell carcinoma of the ovary, hypercalcemic type, is described as a rare, rapidly lethal disease affecting young women. ^[113]C4

Clinical severity and associated presentations

Severe HCM may require renal replacement therapy. A retrospective nephrology-unit study evaluated adults with severe hypercalcemia requiring acute hemodialysis over 84 months and examined etiologies, clinical and biochemical presentation, mortality, and changes during the COVID-19 pandemic. ^[6]B3b HCM can also present with acute pancreatitis, although this combination is uncommon: a systematic review identified 37 published cases, with mean presenting corrected calcium of 14.5 mg/dL; parathyroid carcinoma and multiple myeloma each accounted for 21.6% of reported cases. ^[15]C4 In hospitalized populations, hypercalcemia is associated with increased mortality risk, supporting its use as a marker of serious underlying illness even when malignancy is not the cause. ^[155] A modern Australian tertiary-hospital study similarly examined the causes and mortality associated with inpatient hypercalcemia, reflecting changing contemporary patterns as the prevalence of malignancy and other underlying diseases evolves. ^[156]

Overview

Hypercalcemia of malignancy (HCM) is a metabolic complication of advanced cancer and is reported in approximately 10%–20% of adults with advanced malignancies. ^[8]B3b It is a palliative-care emergency because severe hypercalcemia can produce multisystem complications and is associated with poor prognosis. ^[162] In children, HCM is substantially less frequent, occurring in <1% of pediatric cancer cases, with reported estimates of 0.4%–1.0%. ^[32]D5 Pediatric HCM is more often associated with hematologic malignancy, particularly acute lymphoblastic leukemia, whereas adult cases are more commonly linked to solid tumors. ^[32]D5

Principal malignant mechanisms

The major recognized mechanism is humoral hypercalcemia of malignancy (HHM), in which tumor-derived parathyroid hormone-related protein (PTHrP) increases serum calcium. ^[24]C4 PTHrP is produced physiologically by normal breast epithelial cells but can also be produced by breast and other cancers. ^[26]B2a It shares structural similarity with parathyroid hormone (PTH) and binds the same receptor, thereby promoting PTH-like calcium-regulatory effects. ^[24]C4 PTHrP-associated HHM is reported across gynecologic malignancies, although the available literature is heterogeneous and largely consists of reported cases mapped in a scoping review. ^[24]C4

A second mechanism is local skeletal disease, particularly tumor-driven remodeling in bone metastases. ^[22]D5 Breast cancer cells can release PTHrP, receptor activator of nuclear factor-κB ligand (RANKL), and transforming growth factor-β (TGF-β), disrupting bone homeostasis through osteoclast activation and osteoblast dysregulation. ^[22]D5 This creates a reinforcing tumor–bone cycle in which the bone microenvironment supports tumor persistence while tumor-derived signals increase skeletal calcium release. ^[22]D5 Breast cancer bone metastases account for approximately 70% of metastatic breast cancer cases, making this pathway clinically important in that disease. ^[22]D5

Not all malignancy-associated hypercalcemia conforms to classical osteoclast-mediated osteolysis. A reported patient with high-risk biclonal IgA plasma-cell myeloma developed extreme PTH-independent hypercalcemia, with calcium reaching 17.4 mg/dL, hyperphosphatemia, no marrow osteoclasts, and no osteolytic lesions. ^[160]C The authors characterized the episode as a rare non-osteoclastic bone-remodeling mechanism; hypercalcemia resolved with supportive treatment alone within eight days, although the temporal relationship to a second Moderna mRNA-1273 vaccine dose was reported and does not establish causation. ^[160]C

Tumor types and clinical associations

HCM is described in advanced head and neck squamous-cell carcinoma, where hypercalcemia at diagnosis was defined as albumin-corrected calcium >2.6 mmol/L (10.4 mg/dL). ^[8]B3b In a contemporary pediatric solid-tumor cohort, prolonged hypercalcemia was defined as sustained serum calcium ≥11.5 mg/dL for >1 week; the study identified 39 hospitalized patients younger than 21 years, underscoring the rarity of this presentation. ^[16]B3b In advanced cancer patients receiving palliative care, the prevalence of hypercalcemia and its associated clinical factors have been evaluated in a 155-patient Bangladeshi cohort, although prevalence estimates from that setting should not be generalized to all cancer populations. ^[162]

PTHrP elevation is not synonymous with malignancy. In a retrospective study of 236 patients with hypercalcemia and elevated PTHrP above sex-specific thresholds—>2.3 pmol/L in men and >3.4 pmol/L in women—only 58 had known cancer; the remainder had defined nonmalignant diagnoses. ^[33]B2b Thus, PTHrP results must be interpreted with the clinical context rather than used as an isolated diagnostic confirmation of HCM. ^[33]B2b In breast cancer, a 2026 systematic review and meta-analyses specifically evaluated associations between tumor or circulating PTHrP, tumor characteristics, calcium levels, relapse, and survival, reflecting ongoing uncertainty about whether PTHrP is solely a mediator of hypercalcemia or also a marker of tumor biology. ^[26]B2a

Important malignant and nonmalignant mimics

Parathyroid carcinoma is a rare malignant endocrine tumor that causes severe hypercalcemia through excessive PTH secretion and therefore represents a PTH-dependent malignant cause distinct from typical PTHrP-mediated HHM. ^[34]C4 Its clinical manifestations may include skeletal fragility, nephrolithiasis, neuromuscular symptoms, cardiovascular disturbances, and neurocognitive abnormalities. ^[34]C4 Primary hyperparathyroidism from parathyroid adenoma remains an important alternative explanation for hypercalcemia; a large retrospective series of 561 surgical patients included 78 giant adenomas weighing >3.5 g, with bone pain and renal calculi among common presentations. ^[159]

Disordered vitamin D metabolism can also mimic or compound malignant hypercalcemia. Loss-of-function CYP24A1 mutations reduce degradation of 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 and may cause hypercalcemia with nephrocalcinosis and nephrolithiasis, including in patients who also have primary hyperparathyroidism. ^[52]C4 Conversely, pharmacologic 1,25-dihydroxyvitamin D3 exposure can itself cause hypercalcemia at doses needed for anticancer activity, limiting clinical translation of vitamin-D-based strategies. ^[163]D

Emerging tumor-microenvironment links

Hypoxic cancer-associated fibroblasts in colorectal cancer have been investigated in relation to a PTHrP–vitamin D–renin–angiotensin-system axis, suggesting that stromal signaling may influence tumor biology, although these findings do not establish a direct cause of HCM in patients. ^[21]D5 In non-small-cell lung cancer, hypercalcemia was associated with altered levels of selected circulating cytokines but not with a significant difference in peripheral lymphocyte distribution, supporting an association between calcium disturbances and systemic immune signaling rather than proving a causal immune mechanism. ^[39]C4

Overview

Hypercalcemia is a clinically important metabolic complication of malignancy and may occur through more than one mechanism. The reviewed literature describes malignant hypercalcemia as commonly related to tumor-derived mediators that stimulate osteoclast activity and osteolysis. Less commonly, increased extrarenal conversion of 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D may contribute, particularly in granulomatous disorders such as sarcoidosis. ^[225]D Calcium homeostasis is physiologically regulated by parathyroid hormone, calcitonin, and 1,25-dihydroxyvitamin D; malignant hypercalcemia may therefore reflect dysregulation of pathways that are normally involved in maintaining calcium concentration. ^[225]D

Presentation in high-risk neuroblastoma

A large retrospective analysis of 350 children registered in the German Neuroblastoma trials NB97 and NB04 found that hypercalcemia was frequent during treatment with 13-cis-retinoic acid (13-cisRA). These patients had high-risk neuroblastoma and had received high-risk treatment protocols, including myeloablative chemotherapy with autologous stem-cell transplantation or maintenance therapy, followed by 13-cisRA between January 2000 and December 2010. ^[42]B2b Hypercalcemia was reported in 78 of 350 patients (22.3%), while 37 patients (10.6%) developed severe toxicity classified as Common Terminology Criteria for Adverse Events grade 3 or 4. ^[42]B2b

The study specifically evaluated the frequency of hypercalcemia, associated symptoms, treatment, and potential risk factors. ^[42]B2b The available abstract identifies hypercalcemia as a known adverse effect of retinoid therapy but does not provide a complete symptom inventory, the serum-calcium values, or the detailed clinical characteristics of each episode. ^[42]B2b Accordingly, the presence and severity of symptoms should be assessed clinically rather than inferred from the treatment exposure alone. The evidence supports maintaining awareness of hypercalcemia throughout 13-cisRA therapy, particularly because clinically significant grade 3 or 4 events occurred in a substantial minority of affected patients. ^[42]B2b

Presentation in acute lymphoblastic leukemia

Severe hypercalcemia is described as a rare complication of acute lymphoblastic leukemia (ALL). ^[224]D A report of two patients with ALL and the E2A-HLF fusion gene documented severe hypercalcemia after relapse occurring three months after chemotherapy. ^[224]D The cases involved B-cell lymphoblastic leukemia associated with the t(17;19)(q22;p13) translocation, which generates the E2A-HLF fusion gene. ^[224]D In both reported patients, hypercalcemia developed in the setting of relapsed disease, and the hypercalcemia symptoms were corrected or alleviated after further chemotherapy. ^[224]D

These cases indicate that severe hypercalcemia may accompany a particular biologic and cytogenetic form of relapsed B-cell ALL, although the report concerns only two patients and does not establish that E2A-HLF is required for hypercalcemia in ALL. ^[224]D The available abstract does not enumerate the symptoms, serum-calcium concentrations, or specific supportive treatments used. ^[224]D

Clinical assessment

The reviewed sources emphasize that hypercalcemia may be asymptomatic or symptomatic, but the abstracts supplied here do not define a complete symptom pattern or provide a diagnostic calcium threshold. ^{[42]B2b[224]D[225]D} Clinical evaluation should therefore document symptoms, cancer status, recent treatment exposure, and possible alternative causes. Malignancy is a frequent cause, but primary hyperparathyroidism and granulomatous disease remain relevant considerations because increased parathyroid hormone production and parathyroid-hormone-independent vitamin D activation are recognized causes of elevated calcium. ^[225]D

When hypercalcemia occurs during cancer therapy, the clinical context is important: 13-cisRA exposure is relevant in high-risk neuroblastoma, whereas relapse and E2A-HLF-associated disease are relevant in the reported ALL cases. ^{[42]B2b[224]D} The cited literature supports prompt recognition and treatment of clinically significant hypercalcemia, but the supplied abstracts do not provide a standardized symptom-based severity algorithm or a universal serum-calcium cutoff. ^{[42]B2b[224]D[225]D}

Recognize and confirm hypercalcemia

Hypercalcemia of malignancy (HCM) should be considered a time-sensitive metabolic emergency in a patient with cancer, particularly when hypercalcemia is acute, symptomatic, severe, or accompanied by clinical deterioration. ^{[29]D5[32]D5[162]} Confirm the abnormality with repeat serum calcium testing and assessment of albumin-corrected calcium; measurement of ionized calcium is useful when albumin concentration, acid–base status, or critical illness may make total calcium unreliable. ^{[29]D5[167][55]C4} In a contemporary multicenter cancer cohort, malignancy-associated hypercalcemia was defined as albumin-corrected calcium ≥10.5 mg/dL. ^[227] Pediatric investigators used a more stringent definition of sustained hypercalcemia—serum calcium ≥11.5 mg/dL for more than 1 week—because transient abnormalities may have different clinical implications. ^[16]B3b

Assess severity and complications concurrently rather than waiting for the etiologic work-up, because HCM may cause renal insufficiency, dehydration, gastrointestinal symptoms, neurocognitive changes, and other potentially life-threatening manifestations. ^{[29]D5[16]B3b[32]D5} The diagnostic assessment should include renal function, phosphate, magnesium, albumin, alkaline phosphatase, and an electrocardiographic or clinical assessment when symptoms or marked calcium elevation suggest cardiovascular or neurologic risk. ^{[29]D5[167][50]D5}

Use parathyroid hormone to separate PTH-dependent from PTH-independent disease

Obtain intact parathyroid hormone (PTH) early. A suppressed PTH supports PTH-independent hypercalcemia and should prompt evaluation for HCM, vitamin-D-mediated disease, medication effects, and other non-parathyroid causes; an elevated or inappropriately normal PTH suggests primary or tertiary hyperparathyroidism rather than classic PTH-independent HCM. ^{[29]D5[51]C4[167]} Primary hyperparathyroidism is a frequent alternative explanation for hypercalcemia and requires biochemical interpretation using calcium, PTH, phosphate, vitamin D, renal function, and urinary calcium rather than calcium concentration alone. ^[52]C4[167]

In chronic kidney disease, secondary and tertiary hyperparathyroidism can overlap clinically and biochemically; markedly increased PTH with hypercalcemia and the patient’s renal history may indicate tertiary disease. ^[51]C4 Persistent hypercalcemia after parathyroidectomy should not automatically be attributed to recurrent primary hyperparathyroidism, because coexisting disorders of vitamin-D metabolism, including rare CYP24A1-related impaired vitamin-D catabolism, can produce hypercalcemia with nephrocalcinosis or nephrolithiasis. ^[52]C4

Evaluate PTHrP and other malignancy mechanisms

When PTH is suppressed and malignancy is suspected, measure PTH-related peptide (PTHrP), particularly in patients with advanced cancer or clinical features compatible with humoral HCM. A Korean multicenter study classified PTHrP-mediated HCM as PTHrP >1.1 pmol/L and found that PTHrP-mediated and non-PTHrP-mediated hypercalcemia were distinguishable using this threshold in patients with confirmed malignancy and albumin-corrected calcium ≥10.5 mg/dL. ^[227] However, PTHrP elevation is not cancer-specific: in a retrospective series of 236 patients with hypercalcemia and elevated PTHrP, many patients had nonmalignant diagnoses, so the result must be interpreted with the clinical context and cancer evaluation rather than used as a stand-alone diagnosis. ^[33]B2b

Assay interpretation requires attention to laboratory reference ranges and sex-specific thresholds. One study defined an elevated PTHrP result as >2.3 pmol/L in men and >3.4 pmol/L in women, whereas another used >1.1 pmol/L for classification of PTHrP-mediated HCM. ^[33]B2b[227] These differing cutoffs demonstrate that PTHrP results should be interpreted against the reporting laboratory’s assay and reference interval. ^[33]B2b[227]

If PTHrP is not elevated, investigate osteolytic and cytokine-mediated mechanisms, hematologic malignancy, and vitamin-D-mediated hypercalcemia. ^[29]D5[32]D5 Measurement of 25-hydroxyvitamin D and, when clinically indicated, 1,25-dihydroxyvitamin D helps assess vitamin-D excess or calcitriol-mediated disease; this is particularly relevant in lymphoid malignancies and in patients with nephrolithiasis, nephrocalcinosis, or unexplained hypercalcemia. ^[29]D5[52]C4 Multiple myeloma and other hematologic cancers should be considered when hypercalcemia coexists with anemia, renal dysfunction, bone pain, lytic lesions, or a monoclonal protein. ^{[29]D5[46]B2b}

Identify the underlying malignancy or progression

The cancer evaluation should include directed history and examination, review of tumor type and disease status, medication and supplement exposure, renal history, and imaging guided by symptoms and examination. ^[29]D5[50]D5 Imaging may identify osteolytic metastases or a previously unrecognized primary tumor; severe hypercalcemia with extensive osteolytic lesions has been described in lung carcinoma. ^[54]C4 In children, HCM is uncommon—reported in less than 1% of pediatric cancers—and is more often associated with hematologic malignancy, particularly acute lymphoblastic leukemia, than with adult-pattern solid tumors. ^[32]D5 Pediatric evaluation should therefore include age-appropriate assessment for leukemia, lymphoma, and solid tumors rather than assuming a solid-tumor cause. ^{[16]B3b[32]D5}

In patients with monoclonal gammopathy of undetermined significance, hypercalcemia alone has limited specificity for progression to multiple myeloma. In a screening cohort, 7.5% of individuals with MGUS had hypercalcemia at least once, 48.7% of those had persistent hypercalcemia, and only 3.2% of patients with persistent hypercalcemia had multiple myeloma; all myeloma cases had concurrent bone disease. ^[46]B2b Persistent or recurrent hypercalcemia in MGUS should therefore trigger assessment for bone lesions and other myeloma-defining features rather than being attributed to MGUS automatically. ^[46]B2b

Practical diagnostic sequence

A practical sequence is: confirm calcium elevation and severity; obtain PTH; if PTH is suppressed, measure PTHrP and evaluate vitamin-D metabolites, renal function, medications, hematologic disease, and skeletal disease; if PTH is elevated or inappropriately normal, evaluate primary or tertiary hyperparathyroidism; then use targeted laboratory testing and imaging to establish the mechanism and identify active or progressive malignancy. ^{[29]D5[51]C4[52]C4[167][227]} Urgent treatment should proceed in parallel when hypercalcemia is severe or symptomatic, because diagnostic clarification should not delay stabilization. ^[29]D5[32]D5

Scope and evidence limitations

The supplied evidence does not include a randomized trial, prospective cohort, or systematic review specifically evaluating the emergency treatment of hypercalcemia of malignancy (HCM), nor does it provide comparative evidence for intravenous fluids, calcitonin, glucocorticoids, dialysis, or dosing schedules for acute calcium reduction. The available evidence concerns antiresorptive therapy for skeletal complications, bone health, or medication-related osteonecrosis of the jaw (MRONJ), so use in HCM must be regarded as extrapolative rather than directly supported by these references ^{[61]A1a[174][175][60]A1b}. The other supplied reports address pancreatic surgery, prostate-specific antigen kinetics, epcoritamab-associated cytokine-release syndrome, thyroid disease, or unrelated diagnostic and surgical topics and do not inform acute HCM management ^{[65]A1b[64]B2b[74]B2b[77]B2b[177][178]C[179][180]}.

Immediate assessment and stabilization

Patients with suspected HCM should undergo urgent clinical assessment of neurologic, gastrointestinal, renal, and cardiovascular manifestations, with severity determined from the corrected or ionized calcium concentration, symptoms, renal function, hydration status, and rate of rise. However, none of the permitted references reports validated acute-care thresholds or outcome data for this approach; therefore, local emergency oncology or endocrine protocols should determine the precise triage and monitoring pathway ^[61]A1a[174].

Initial management should simultaneously address volume status, medication contributors, the underlying malignancy, and the need for a rapid antiresorptive intervention. The permitted evidence does not establish the efficacy or safety of any specific crystalloid regimen, loop diuretic strategy, calcitonin regimen, glucocorticoid regimen, or renal replacement strategy in HCM ^[61]A1a[174]. A loop diuretic should therefore not be presented as routine calcium-lowering therapy on the basis of the supplied literature alone ^[61]A1a[174].

Antiresorptive therapy

Antiresorptives are the principal disease-directed treatment class supported indirectly by the supplied cancer literature. In breast-cancer bone metastases, denosumab and bisphosphonates were evaluated for skeletal-related events, including pain, fractures, and radiation or surgery to bone; a 2026 systematic review and meta-analysis included five publications representing four unique studies, comprising three randomized trials and one retrospective cohort ^[61]A1a. A separate network meta-analysis included 22 studies and 14,934 patients with breast-cancer bone metastases and evaluated pamidronate, zoledronate, clodronate, and ibandronate for skeletal-related outcomes ^[175]. These studies concern prevention or management of skeletal complications rather than acute HCM, and their results should not be interpreted as direct evidence of superiority for emergency calcium reduction ^[61]A1a[175].

Denosumab has also been studied in a phase 2 single-arm trial with pembrolizumab in pretreated advanced clear-cell renal-cell carcinoma, using 120 mg subcutaneously on days 1, 8, and 22, followed by every-3-week administration until progression, unacceptable toxicity, or a maximum of 24 months ^[62]C4. This schedule was an oncology trial regimen and is not evidence for acute HCM dosing or for combining denosumab with pembrolizumab specifically to lower calcium ^[62]C4.

In men with non-metastatic prostate cancer receiving androgen-deprivation therapy, a systematic review identified 26 randomized controlled trials, including 17 intravenous-bisphosphonate trials, five oral-bisphosphonate trials, and two denosumab trials, with two trials including both treatment classes ^[174]. The review evaluated bone health and fractures rather than HCM; oral bisphosphonates had no demonstrated effect on 12-month fracture incidence, with RR 0.57 (95% CI 0.10–3.23) and very-low-certainty evidence ^[174]. These findings do not support oral bisphosphonates as acute treatment for HCM ^[174].

Renal, dental, and metabolic precautions

Choice and administration of an antiresorptive should include renal, electrolyte, dental, and treatment-goal review, but the supplied abstracts do not provide a complete acute-HCM renal dosing algorithm or comparative guidance for patients with severe kidney dysfunction ^{[61]A1a[174][175]}. In metastatic hormone-sensitive prostate cancer, a prospective phase II study assessed zoledronic acid alongside androgen deprivation and enzalutamide using bone-density, trabecular-score, alkaline-phosphatase, and CTX outcomes over 18 months; this was a bone-health study and not an acute-calcium study ^[60]A1b.

MRONJ is a clinically important toxicity when potent antiresorptives are used in oncology. A retrospective breast-cancer cohort compared patients who developed MRONJ after zoledronic acid or denosumab exposure and specifically examined drug-related clinical characteristics ^[63]B2b. In a multiple-myeloma dental-extraction cohort, 13 of 320 patients (4.1%) developed MRONJ after pre-autologous-transplant extractions; periodontal disease was the most common reason for extraction among affected patients ^[176]. Conservative-management data found mean sequestrum formation and detection at 6.82 ± 5.44 months after the dental procedure ^[76]C4. These findings support dental-risk assessment and avoidance of unnecessary invasive dental procedures, but they do not justify delaying urgent calcium-lowering therapy when HCM is life-threatening ^{[63]B2b[76]C4[176]}.

Practical conclusion

For acute HCM, stabilize and monitor the patient urgently, investigate the malignancy-related mechanism and reversible contributors, and involve oncology, endocrinology, nephrology, and dental services when appropriate. Within the permitted evidence base, antiresorptives are supported for cancer-associated skeletal disease but not directly validated for emergency HCM; drug selection, timing, and monitoring must therefore follow current institutional protocols and product-specific safety guidance rather than the studies cited here ^{[61]A1a[174][175]}.

Scope and evidence relevance

The supplied evidence does not directly evaluate long-term therapy for hypercalcemia of malignancy (HCM), nor does it establish a maintenance regimen for preventing recurrent cancer-associated hypercalcemia. The most directly relevant study concerns prolonged denosumab use in giant-cell tumour of bone (GCTB), a locally aggressive bone tumour rather than a conventional malignant cause of HCM ^[233]C. The remaining studies evaluate maintenance strategies directed at the underlying malignancy, and their results should not be interpreted as evidence that these regimens correct or prevent HCM [228-232,184-185,231,189,191,234-238,195-196].

Denosumab and prolonged antiresorptive treatment

Denosumab has been used in GCTB as neoadjuvant therapy before curettage, before en-bloc resection, as definitive treatment for unresectable disease, and as long-term therapy for recurrent or metastatic disease ^[233]C. A retrospective cohort from a tertiary orthopaedic centre reviewed patients treated between 2010 and 2023 and categorized treatment according to therapeutic intent, including long-term administration ^[233]C. The abstract establishes that indication-specific outcomes, treatment duration, recurrence patterns, and prolonged administration were assessed, but it does not provide sufficient numerical outcome data to define an HCM-specific duration, dosing interval, discontinuation strategy, or monitoring schedule ^[233]C. Therefore, denosumab should not be described on the basis of this study alone as a validated maintenance treatment for HCM ^[233]C.

Maintenance treatment directed at the primary cancer

In advanced ovarian cancer responding to platinum chemotherapy, an updated systematic review and meta-analysis evaluated olaparib maintenance versus placebo or standard care across biomarker-defined subgroups and first-line or recurrent settings, with overall survival and progression-free survival as primary endpoints; the supplied abstract does not report the pooled effect estimates or safety results ^[228]. In newly diagnosed or recurrent endometrial cancer, the phase 3 RUBY Part 2 study evaluated adding niraparib to dostarlimab maintenance after dostarlimab plus carboplatin-paclitaxel, compared with placebo maintenance after placebo plus chemotherapy ^[184]. Updated PRIMA trial analyses assessed niraparib first-line maintenance in newly diagnosed advanced ovarian cancer using longitudinal quality-of-life instruments and examined quality-of-life changes around progression ^[185].

A phase 2 study evaluated intermittent olaparib with neoadjuvant platinum chemotherapy in 36 patients with newly diagnosed, BRCA-mutated, unresectable advanced epithelial ovarian cancer; the study addressed concurrent or neoadjuvant treatment rather than post-treatment HCM prevention ^[235]. A retrospective Japanese study of 28 patients assessed PARP-inhibitor rechallenge after platinum-sensitive recurrence following prior PARP-inhibitor exposure; olaparib was used in 19 patients and niraparib in 9, but this evidence is not specific to HCM ^[238]C.

In advanced HER2-negative oesophagogastric adenocarcinoma, the phase 2 PLATFORM study randomized patients with response or stable disease after 18 weeks of platinum chemotherapy to surveillance or rucaparib 600 mg twice daily; progression-free survival was the primary endpoint, with safety, overall survival, and homologous-recombination-deficiency analyses as secondary or exploratory outcomes ^[231]. In extensive-stage small-cell lung cancer (ES-SCLC), a single-arm phase 2 study treated 60 patients with durvalumab plus platinum-etoposide followed by durvalumab plus olaparib maintenance, while another phase 2 study treated 40 patients with QL1706 plus carboplatin-etoposide followed by QL1706 maintenance until progression ^[193][234]. A multi-omics analysis explored DNA hypomethylation as a subgroup marker for benefit from durvalumab plus olaparib maintenance ^[193]. A retrospective ES-SCLC analysis identified liver metastasis, maintenance therapy, albumin, and neutrophil-to-lymphocyte ratio among prognostic variables in 109 patients receiving serplulimab-based immunochemotherapy ^[191]. These studies may affect tumour control, but none establishes treatment of HCM ^{[191][193][234]}.

For locally advanced NSCLC in patients aged ≥75 years, a phase 3 trial compared daily low-dose carboplatin with weekly carboplatin plus nab-paclitaxel during concurrent thoracic radiotherapy; durvalumab maintenance was recommended after treatment completion ^[229]. In EGFR-mutated advanced NSCLC with concurrent TP53 mutations, a randomized phase 3 trial compared first-line osimertinib plus chemotherapy with osimertinib alone ^[230]. Neither study provides HCM-specific maintenance evidence [229-230].

Other malignancies and post-transplant maintenance

In standard-risk, newly diagnosed multiple myeloma without upfront transplantation, a phase 3 trial compared continuous lenalidomide maintenance with a fixed 2-year course after proteasome-inhibitor/lenalidomide induction; overall survival was the primary endpoint ^[90]A1b. In AML, quizartinib plus induction and consolidation chemotherapy followed by maintenance monotherapy is being evaluated in the randomized phase 3 QuANTUM-Wild trial for newly diagnosed FLT3-ITD-negative disease ^[189]. Vinorelbine plus low-dose cyclophosphamide is being developed as maintenance in the international INTER-EWING-1 Ewing sarcoma program because relapse risk remains high and the maintenance role is undefined ^[232].

Post-transplant studies include venetoclax plus decitabine maintenance after allogeneic transplantation in 58 high-risk AML/MDS patients, with emphasis on venetoclax exposure, efficacy, and toxicity ^[195]. Claims-based analysis evaluated health-care utilization and costs after AML allogeneic transplantation among patients receiving maintenance versus transplantation alone ^[196]. These findings concern relapse prevention and treatment burden rather than calcium control [195-196].

Practical interpretation for HCM

Maintenance therapy should therefore be individualized according to the underlying cancer, response, renal function, skeletal disease, prior antiresorptive exposure, and recurrence pattern; the supplied references do not provide evidence for a universal HCM maintenance protocol [228-238,90,195-196]. Denosumab is the only reviewed agent used in a long-term skeletal-tumour context, but the available abstract does not justify extrapolating GCTB practice to all patients with HCM ^[233]C.

Children and adolescents

Pediatric hypercalcemia requires an etiologic diagnosis before treatment is attributed to malignancy, because reported causes include malignancy, ketogenic diet, and Williams syndrome. In a multicenter pediatric series, patients ranged from 2 months to 16 years, with peak calcium concentrations of 3.29–5.04 mmol/L; intravenous fluids, calcitonin, and glucocorticoids had been tried before denosumab, and all patients received multiple denosumab doses. ^[101]C4 The report supports specialist use of denosumab when conventional therapy is inadequate, but the evidence is limited to a case series and includes heterogeneous, nonmalignant causes. ^[101]C4

Autosomal dominant hypocalcemia type 1 is not a malignancy-associated disorder but is an important pediatric differential because activating CASR variants cause PTH suppression and abnormal renal calcium handling. In five genetically confirmed children refractory to standard therapy, continuous subcutaneous PTH(1-34) infusion was evaluated over as long as 11 years; standard therapy was associated with renal calcium wasting, hypercalciuria, nephrocalcinosis, and potential renal impairment. ^[201]C PTH infusion should therefore be considered only in specialized management of refractory genetic hypoparathyroid disorders, not as routine treatment for hypercalcemia of malignancy. ^[201]C

Pregnancy

Severe hypercalcemia in pregnancy may be caused by primary hyperparathyroidism rather than malignancy. A 32-year-old woman developed acute pancreatitis near term; after cesarean delivery, calcium remained persistently above 4.0 mmol/L, transient responses to calcium-lowering interventions were followed by recurrence, and PTH was 1,404 pg/mL. Imaging identified a parathyroid lesion, and parathyroid carcinoma was diagnosed. ^[98]C4 Persistent or refractory hypercalcemia with pancreatitis in pregnancy should prompt measurement of PTH and expedited endocrine-surgical assessment, while balancing maternal stabilization and fetal considerations. ^[98]C4

Chronic kidney disease and kidney transplantation

Renal dysfunction both complicates hypercalcemia management and may indicate an alternative diagnosis. Milk-alkali syndrome is characterized by hypercalcemia, metabolic alkalosis, and renal failure; in an 83-year-old man, prolonged consumption of 1.5–2.0 L/day of calcium-containing thermal water caused persistent hypercalcemia and renal insufficiency, which normalized after the exposure stopped. ^[205]C Patients with kidney disease should therefore undergo a detailed review of calcium, alkali, supplements, and unusual mineral-water exposures before attributing hypercalcemia to cancer. ^[205]C

In kidney-transplant recipients, tertiary hyperparathyroidism is a separate PTH-dependent cause of hypercalcemia. A TriNetX study compared parathyroidectomy with cinacalcet and examined the timing of surgery after transplantation; the study was motivated by evidence that parathyroidectomy may be superior to medical management for hypercalcemia and renal-allograft preservation. ^[207]D The 2025 Cochrane review addressed phosphate binders for CKD-mineral and bone disorder, assessing benefits, harms, and comparative effects of binders through 16 December 2024; this evidence concerns phosphate control in CKD and should not be interpreted as direct treatment evidence for hypercalcemia of malignancy. ^[104]A1a

Parathyroid carcinoma and hereditary endocrine syndromes

Parathyroid carcinoma is a rare malignancy characterized commonly by unregulated PTH secretion, severe hypercalcemia, and, in advanced disease, complications from tumor dissemination; available management evidence is largely derived from case reports, case series, and registry studies. Surgical resection remains important for localized and metastatic disease, with newer approaches also emerging. ^[48]D5 Severe skeletal and renal manifestations may be presenting features: a young man developed a pathological fracture after minimal trauma in the setting of parathyroid carcinoma-associated hyperparathyroidism. ^[34]C4

Marked biochemical abnormalities do not establish carcinoma. A series and literature review described three women with symptomatic primary hyperparathyroidism and PTH concentrations of 755–3,547.4 pg/mL whose lesions were adenomas without histopathologic malignancy. ^[105]C4 Conversely, giant parathyroid adenomas—defined as glands weighing more than 3.5 g—formed 78 of 561 surgically treated cases; the mean age was 42 years, 65% were female, and bone pain and renal calculi were frequent presentations. ^[159] MEN1-associated primary hyperparathyroidism is often the earliest MEN1 manifestation; expert review recommends surgery for patients with MEN1 and hypercalcemia, commonly before age 50, with timing influenced by calcium concentration and renal or skeletal complications. ^[28]D5 A case report illustrates that MEN1 may present with hypercalcemia, hypophosphatemia, and concurrent gastrointestinal and pituitary-region disease. ^[170]C

Hematologic malignancy and unusual cancer mimics

Multiple myeloma commonly presents with combinations of anemia, bone pain, renal injury, fatigue, hypercalcemia, and weight loss. ^[100]D5 A report of biclonal IgA myeloma documented extreme PTH-independent hypercalcemia reaching 17.4 mg/dL, with hyperphosphatemia, no marrow osteoclasts, and no osteolytic lesions; calcium normalized within eight days with supportive care and remained normal for nine months. ^[160]C These findings emphasize that severe hypercalcemia in myeloma may not follow the classical osteolytic pattern. ^[160]C

Other nonmalignant mimics include IgG4-related disease presenting with acute kidney injury and calcium 3.69 mmol/L, which improved with prednisone and supportive care. ^[204]C High-volume gluteal PMMA injections have been associated with hypercalcemia, hypercalciuria, nephrolithiasis, and renal insufficiency; in a series of 12 women, injected volumes ranged from 150–900 mL. ^[202]C CYP24A1 loss-of-function can cause persistent vitamin-D-mediated hypercalcemia with nephrocalcinosis and nephrolithiasis despite parathyroidectomy. ^[52]C4 Experimental mouse data further indicate tissue-specific intestinal and renal CYP24A1 effects on vitamin-D and mineral homeostasis, but these findings are not direct human treatment evidence. ^[206]D

Denosumab discontinuation and dialysis

Rebound hypercalcemia is a rare, non-PTH-dependent complication after denosumab cessation. It occurred in a 47-year-old man followed after surgery for parathyroid carcinoma and resolved after denosumab was restarted. ^[102]C4 Calcium should therefore be monitored after discontinuation, particularly when high bone turnover or complex endocrine disease is present. ^[102]C4 Hemodialysis successfully corrected catastrophic iatrogenic hypercalcemia with acute kidney injury in a cat after calcium-gluconate overdose, but this veterinary report cannot establish human indications or dosing. ^[203]C

Overall prognostic significance

Hypercalcemia of malignancy (HCM) is a serious metabolic complication associated with substantial short-term mortality; prognosis depends on tumor type, disease burden, calcium concentration, albumin status, organ dysfunction, and the feasibility of treating the underlying cancer ^{[1]B3b[3]B3b[14]B3b[111]C4[209]}. In a national inpatient analysis of adults hospitalized with solid cancers and HCM, the reported mortality risk was approximately 50% within 1 month of diagnosis ^[3]B3b. A retrospective cohort of patients treated with intravenous diphosphonates reported a median overall survival of 64 days (range, 12–1,955+ days) ^[111]C4. A separate cohort of patients with squamous-cell carcinoma and cancer-associated hypercalcemia (CAH) also reported a median survival of 64 days (range, 1–197 days) from the first hypercalcemic episode ^[14]B3b. These figures derive largely from hospitalized or advanced-disease populations and should not be generalized to all patients with cancer-associated calcium elevation ^{[3]B3b[14]B3b[111]C4}.

Predictors of poor outcome

The severity of hypercalcemia is consistently associated with worse outcomes. In patients with squamous-cell carcinoma, corrected calcium >3.0 mmol/L was independently associated with shorter survival (hazard ratio [HR] 1.45), as were brain metastases (HR 2.58) and hypoalbuminemia (HR 1.40) ^[14]B3b. In the intravenous-diphosphonate cohort, corrected calcium >2.83 mmol/L, albumin <35.5 g/L, squamous-cell carcinoma, bone metastases, and liver metastases were independently associated with poorer survival; corrected calcium above the specified threshold was associated with HR 2.21 and low albumin with HR 2.41 ^[111]C4.

A multicenter Spanish study of 154 hospitalized patients with paraneoplastic hypercalcemia had a median follow-up of only 3.5 weeks (interquartile range, 1.1–11.5 weeks), emphasizing the rapidly fatal course in many inpatients ^[209]. A hospital-based emergency-department study found malignancy to be the underlying cause in 36.4% of hypercalcemic presentations; renal dysfunction was common, with normal renal function documented in only 23.4% of patients ^[208]. In a large general internal-medicine cohort, both calcium level at admission and calcium level before discharge were associated with mortality risk, although the population included patients with nonmalignant as well as malignant causes of calcium abnormalities ^[155].

Tumor-specific outcomes

In multiple myeloma (MM), hypercalcemia was present at diagnosis in 16.8% of patients in a retrospective cohort of 357 newly diagnosed cases and was associated with higher β2-microglobulin, creatinine, phosphorus, and uric acid levels, indicating greater disease burden and organ dysfunction ^[7]B3b. The same study evaluated hypercalcemia caused by humoral effects and bone damage as prognostic factors and found both mechanisms to indicate poor outcomes ^[7]B3b. An earlier cohort of 338 symptomatic MM patients treated with hematopoietic stem-cell transplantation or conventional chemotherapy assessed survival in the context of stage, bone lesions, anemia, and evolving treatment strategies; the study reflects outcomes from patients diagnosed in 2003–2005, before many contemporary therapies were routinely available ^[112]B2b.

At diagnosis, hypercalcemia occurred in approximately 23% of de novo diffuse large B-cell lymphoma (DLBCL) cases and 26% of transformed indolent lymphomas in a retrospective cohort of 305 patients ^[9]B3b. In de novo DLBCL, hypercalcemia was strongly associated with high-risk clinical features and a short diagnosis-to-treatment interval; outcomes were assessed using event-free survival at 24 months ^[9]B3b.

In advanced or locally advanced head and neck squamous-cell carcinoma, hypercalcemia at diagnosis was defined as albumin-corrected calcium >2.6 mmol/L (10.4 mg/dL) and was investigated as a prognostic marker in a 2015–2021 bicentric retrospective cohort ^[8]B3b. The study also evaluated associated phenotypes, mechanisms, and treatment options, supporting the use of hypercalcemia as a marker of aggressive disease in this setting ^[8]B3b.

Gynecologic malignancies show similarly poor outcomes when hypercalcemia is moderate or severe. In a single-institution study, 268 of 5,260 patients with gynecologic malignancies had hypercalcemia; after exclusion of hyperparathyroidism and coexisting malignancies, 256 patients remained, and 82% had mild hypercalcemia ^[18]B3b. Calcium severity was associated with survival ^[18]B3b. A population-based breast-cancer cohort evaluated the relationship between skeletal-related events—including hypercalcemia—and mortality after bone metastases, reflecting the prognostic importance of complications from skeletal disease ^[10]B3b.

Small-cell carcinoma of the ovary of hypercalcemic type (SCCOHT) is an exception in which intensive disease-directed treatment may produce durable survival in selected patients. In a prospective multicenter cohort of 44 women treated with cytoreductive surgery and four to six cycles of PAVEP chemotherapy, patients achieving complete response received high-dose chemotherapy with stem-cell support followed by pelvic radiotherapy; the study was designed to confirm improved outcomes previously observed with this strategy ^[113]C4.

PTHrP-mediated disease and special presentations

PTH-related peptide (PTHrP) is a major mediator of HCM, and PTHrP-mediated hypercalcemia has been associated with poor survival ^{[19]C4[11]B3b}. A Queensland hospital-based series identified 138 patients with persistent hypercalcemia and simultaneously elevated PTHrP and compared malignant with benign etiologies ^[19]C4. A later study included patients with malignancy, calcium >10 mg/dL, and PTHrP >1.1 pmol/L to evaluate associations between PTHrP concentration, calcium level, and mortality ^[11]B3b. A multicenter Korean clinical-data study similarly defined PTHrP-mediated HCM as albumin-corrected calcium ≥10.5 mg/dL with PTHrP >1.1 pmol/L and identified 289 such patients ^[227].

Hypercalcemia-associated acute pancreatitis is uncommon but clinically severe. A systematic review identified 37 cases; mean presenting corrected calcium was 14.5 mg/dL, and parathyroid carcinoma and MM each accounted for 21.6% of reported cases ^[15]C4. Parathyroid carcinoma is usually hormonally functional, with approximately 90% of tumors hypersecreting PTH; consequently, most patients present with marked symptomatic hypercalcemia ^[110]D5.

Practical interpretation

HCM should generally be regarded as a marker of advanced or biologically aggressive malignancy, particularly when calcium is markedly elevated, albumin is low, metastatic disease or organ dysfunction is present, or the tumor is a squamous carcinoma, MM, lymphoma, or advanced gynecologic cancer ^{[7]B3b[9]B3b[14]B3b[18]B3b[111]C4}. Prognosis is driven primarily by control of the underlying malignancy; correction of calcium may improve acute complications but does not by itself eliminate the adverse prognostic significance of HCM ^{[3]B3b[7]B3b[111]C4}.

Scope and evidence limitations

The supplied 2025–2026 references are predominantly disease-specific oncology guidelines and guideline updates, but none is dedicated to hypercalcemia of malignancy or provides a hypercalcemia-specific diagnostic algorithm, treatment threshold, drug dose, monitoring schedule, or outcome comparison. Accordingly, this section should not attribute a calcium threshold or treatment recommendation to these sources. All supplied records are classified as evidence level 1c in the provided evidence list. ^{[239][240][241][211][115]A1c[242][243][116]A1c[117]A1c[130]A1c[131]A1c[213][118]A1c[119]A1c[132]A1c[133]A1c[121]A1c[128]D5[122]A1c[123]A1c}

Guideline-directed cancer management relevant to the underlying malignancy

The references consistently emphasize that management of the underlying cancer should be guided by disease subtype, stage, biomarkers, prior treatment, response, and patient-specific factors; however, they do not specify how treatment of hypercalcemia should be integrated with these decisions. The NCCN B-cell lymphoma guideline describes mantle cell lymphoma as heterogeneous and highlights covalent BTK inhibitor-based regimens, measurable residual disease assessment, and predefined maintenance or continuous therapy; pirtobrutinib and CAR T-cell therapy are identified as options for refractory or progressive disease after covalent BTK inhibitor exposure. ^[239]

For esophageal and esophagogastric-junction cancers, the NCCN update addresses advanced squamous cell carcinoma and adenocarcinoma, biomarker testing, immunotherapy, and systemic therapy for palliation, survival, and quality-of-life goals. It does not report hypercalcemia-specific management. ^[240] The Pan-Asian adapted ESMO guideline addresses diagnosis, treatment, and follow-up of hepatocellular carcinoma and was adapted from the 2025 ESMO guideline through a regional expert-consensus process; the supplied abstract does not provide recommendations for malignancy-associated hypercalcemia. ^[241]

The pleural mesothelioma guideline provides evaluation and treatment recommendations for pleural mesothelioma and notes that the NCCN guidance is updated annually according to available clinical evidence and panel consensus. The supplied record does not identify calcium-related recommendations. ^[211] The breast cancer guideline covers carcinoma in situ, invasive disease, Paget disease, phyllodes tumor, inflammatory breast cancer, pregnancy, and recurrent or metastatic disease stratified by hormone-receptor and HER2 status, prior therapy, and disease-free interval; the supplied abstract mentions supportive care but does not provide hypercalcemia-specific details. ^[115]A1c

The ASCO living guidelines for stage IV non-small-cell lung cancer address treatment according to driver alterations and are designed for rapidly changing evidence, with regular updates by a standing expert panel. ^{[242][130]A1c} The companion guideline addresses stage IV disease without driver alterations and similarly emphasizes regularly updated recommendations and clinician judgment. ^[131]A1c The NCCN NSCLC guideline updates targeted-therapy recommendations based on regulatory approvals and clinical data, particularly for advanced or metastatic disease with actionable biomarkers. ^[133]A1c None of these records supplies a malignancy-associated hypercalcemia threshold or treatment protocol.

Hematologic malignancy and supportive-care context

The ASCO multiple myeloma living guideline states that treatment is rapidly evolving, should be individualized, and includes recommendations for newly diagnosed and previously treated relapsed or refractory disease. ^[213] The NCCN multiple myeloma guideline likewise describes a rapidly evolving treatment landscape and provides a framework for diagnosis, workup, treatment, and follow-up, with the supplied selection focused on newly diagnosed disease. ^[122]A1c These references establish the importance of disease-directed assessment but do not provide calcium-lowering treatment recommendations.

The NCCN acute myeloid leukemia update describes AML as a heterogeneous malignancy involving clonal myeloid-blast expansion and notes annual guideline revision based on clinical trials and biologic prognostic information. ^[117]A1c The NCCN bladder cancer guideline covers non-muscle-invasive, muscle-invasive, and metastatic disease, with the featured content focused on diagnostic workup and management of non-muscle-invasive disease. ^[118]A1c The NCCN prostate cancer update addresses staging, risk assessment, active surveillance, focal therapy, and nonmetastatic disease. ^[119]A1c These sources do not address hypercalcemia of malignancy.

Additional guideline domains

The melanoma guideline discusses diagnosis, staging, follow-up, and risk factors including phenotype, medical history, genetic predisposition, and environmental exposure. ^[116]A1c The vaginal cancer guideline addresses diagnostic evaluation, staging, pathology, radiation, primary therapy, advanced disease, and relapse; some systemic-treatment recommendations are extrapolated from cervical cancer because of disease rarity and biologic similarities. ^[121]A1c The soft-tissue sarcoma guideline update focuses on surgical management and systemic therapy across subtypes. ^[123]A1c None of the supplied abstracts contains a hypercalcemia-specific recommendation.

ASCO guidance on circulating tumor DNA addresses testing in solid tumors and lymphoma and cautions that guidance is not a comprehensive or definitive treatment guide and should be applied with independent clinical judgment. ^[243] The ESMO EnLiST framework standardizes designation of systemic-therapy lines in solid tumors through multidisciplinary Delphi consensus, supporting consistent treatment-line terminology but not calcium management. ^[128]D5 The NCCN distress-management guideline addresses identification, referral, psychosocial interventions, and implementation of distress standards; it is supportive-care guidance rather than a hypercalcemia guideline. ^[132]A1c

Practical conclusion for this page

These references support treating the underlying malignancy according to current disease-specific NCCN, ASCO, or ESMO guidance, while recognizing that the supplied evidence does not establish any validated calcium threshold for intervention, any preferred calcium-lowering drug, or any evidence-based monitoring interval for hypercalcemia of malignancy. ^{[239][240][241][211][115]A1c[242][243][116]A1c[117]A1c[130]A1c[131]A1c[213][118]A1c[119]A1c[132]A1c[133]A1c[121]A1c[128]D5[122]A1c[123]A1c} A dedicated hypercalcemia guideline, primary clinical trial, or systematic review is required before adding claims about diagnostic thresholds, intravenous fluids, antiresorptive therapy, calcimimetics, glucocorticoids, dialysis, or treatment sequencing.

Scope of prevention

Prevention of hypercalcemia of malignancy (HCM) depends primarily on controlling the underlying cancer and identifying patients at risk for osteolytic or osteoblastic skeletal disease. The updated evidence base is dominated by studies of bone-modifying agents (BMAs) used to prevent skeletal-related events (SREs), cancer-treatment-induced bone loss, or fractures; these studies should not be interpreted as direct evidence that BMAs prevent every episode of HCM. ^{[61]A1a[135]A1a[174][214]}

Baseline assessment and supportive care

Patients considered for prolonged antiresorptive therapy should undergo individualized assessment of fracture risk, skeletal disease, renal function, calcium status, vitamin D status, dental health, and the anticipated duration of therapy. The reviewed literature identifies calcium and vitamin D supplementation as part of supportive management in bone-protective treatment protocols, including denosumab treatment in recurrent or refractory osteosarcoma. ^{[135]A1a[140]C4} Myeloma guidance continues to address bisphosphonates, denosumab, and osteonecrosis as central components of bone-disease management. ^[214]

Dental evaluation and preventive dental care are particularly important because medication-related osteonecrosis of the jaw (MRONJ) is a recognized concern during BMA treatment and is relevant when deciding treatment duration or discontinuation. ^{[61]A1a[134]A1c[214][222]} Treatment plans should therefore incorporate oral-hygiene optimization, avoidance of unnecessary invasive dental procedures during active therapy when feasible, and coordinated dental–oncology follow-up. ^{[134]A1c[214][222]}

Choosing and monitoring antiresorptive therapy

Denosumab and bisphosphonates are established options for reducing skeletal complications in patients with bone metastases, although their comparative benefits and harms vary by cancer type, endpoint, and certainty of evidence. ^[61]A1a In breast-cancer bone metastases, a systematic review comparing denosumab with bisphosphonates evaluated SREs, fractures, radiation or surgery, renal and metabolic adverse events, MRONJ, and serious or treatment-related toxicity; the evidence included four unique studies, comprising three randomized trials and one retrospective cohort. ^[61]A1a

For non-metastatic prostate cancer treated with androgen-deprivation therapy (ADT), a 2026 systematic review included 26 randomized controlled trials: 17 intravenous-bisphosphonate trials, 5 oral-bisphosphonate trials, and 2 denosumab trials, with 2 trials including both an oral bisphosphonate and denosumab. ^[174] Oral bisphosphonates did not demonstrate a clear reduction in fractures at 12 months, with a reported risk ratio of 0.57 (95% CI, 0.10–3.23) and very low certainty of evidence. ^[174] This uncertainty supports risk-adapted rather than automatic antiresorptive treatment for every man receiving ADT. ^[174]

In early breast cancer, BMAs are used to mitigate cancer-treatment-induced bone loss, and updated guidance addresses treatment initiation, timing, and agent selection. ^[134]A1c A systematic review in non-metastatic breast cancer evaluated bisphosphonates, denosumab, calcium, and vitamin D for effects on bone mineral density, fractures, bone-turnover markers, and safety outcomes. ^[135]A1a Denosumab should not presently be assumed to provide anticancer benefit in early breast cancer: the randomized GeparX study found no improvement in pathological complete response, and long-term outcomes were assessed for invasive disease-free, distant disease-free, overall, and locoregional recurrence-free survival. ^[144]A1b A separate randomized window-of-opportunity study investigated denosumab as an immune and biological modulator in HER2-negative early breast cancer, reflecting an investigational rather than established prevention strategy. ^[145]A1b

Disease-specific prevention and surveillance

In multiple myeloma, updated 2025 consensus guidance specifically reviews zoledronic acid, pamidronate, denosumab, and osteonecrosis for myeloma bone disease. ^[214] In metastatic castration-sensitive prostate cancer, the role of BMAs remains unclear; a retrospective study characterized symptomatic skeletal events among 318 patients with bone metastases treated with denosumab. ^[218] Real-world studies have also examined denosumab-associated survival and SRE outcomes in Asian men with metastatic castration-resistant prostate cancer, in lung-cancer populations with bone metastases, and in stage IV lung adenocarcinoma receiving denosumab 120 mg subcutaneously every 4 weeks ± 7 days. ^{[220][221][223]} Because these are observational datasets, they support risk stratification and hypothesis generation rather than definitive causal treatment recommendations. ^{[218][220][221][223]}

Duration, discontinuation, and future directions

The optimal duration of denosumab for bone metastases remains uncertain because prolonged exposure may reduce skeletal complications but increases cumulative concern regarding MRONJ. ^[222] A retrospective cohort of 178 patients who discontinued denosumab after at least 6 doses evaluated the incidence, timing, and predictors of subsequent symptomatic skeletal events; a landmark analysis also examined patients treated for at least 2 years. ^[222] Discontinuation should therefore be planned rather than treated as an automatically risk-free endpoint, with reassessment of skeletal disease activity, fracture risk, dental status, and alternative antiresorptive strategies. ^[222]

Future research should prioritize randomized comparisons of denosumab, intravenous and oral bisphosphonates; validated biomarkers for skeletal-event and HCM risk; optimal treatment intervals; safe discontinuation or transition protocols; and integration of BMAs with systemic anticancer therapy. ^{[61]A1a[135]A1a[174][214][222]} RANKL inhibition is also being investigated as an immune or tumor-microenvironment intervention in renal-cell carcinoma, breast cancer, dermatologic malignancies, osteosarcoma, and giant-cell tumor of bone, but current evidence includes phase II, observational, mechanistic, or meta-analytic studies and should not be extrapolated to routine HCM prevention. ^{[62]C4[145]A1b[217][219][140]C4[146]A1a[215][216]} In giant-cell tumor of bone, updated recommendations continue to position surgery as the main treatment and reserve denosumab for unresectable disease or situations in which resection would cause severe morbidity. ^[215] Perioperative denosumab remains an area of uncertainty because its association with local recurrence after surgical management has produced conflicting findings. ^[146]A1a Denosumab has also been studied in recurrent or refractory osteosarcoma, with calcium and vitamin D supplementation incorporated into the treatment protocol, but single-arm phase II evidence is insufficient to establish preventive use for HCM. ^[140]C4